期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 3, 期 8, 页码 620-625出版社
AMER CHEMICAL SOC
DOI: 10.1021/ml300042k
关键词
hypoxia; solid tumors; p300; HIF arylsulfonamide inhibitors; binding model; QSAR; KCN1
资金
- EmTechBio
- Southeastern Brain Tumor Foundation
- University Research Council
- NIH [R01 CA86335, CA116804, P30 CA138292, GM084933, GM86925, P50 CA128301]
- V Foundation
- Max Cure Foundation
- Samuel Waxman Cancer Research Foundation
Hypoxia inducible factors (HIFs) are transcription factors that activate expression of multiple gene products and promote tumor adaptation to a hypoxic environment. To become transcriptionally active, HIFs associate with cofactors p300 or CBP. Previously, we found that arylsulfonamides can antagonize HIP transcription in a bioassay, block the p300/HIF-1 alpha interaction, and exert potent anticancer activity in several animal models. In the present work, KCN1-bead affinity pull down, C-14-labeled KCN1 binding, and KCN1-surface plasmon resonance measurements provide initial support for a mechanism in which KCN1 can bind to the CH1 domain of p300 and likely prevent the p300/HIF-1 alpha assembly. Using a previously reported NMR structure of the p300/HIP-1 alpha complex, we have identified potential binding sites in the p300-CH1 domain. A two-site binding model coupled with IC50 values has allowed establishment of a modest ROC-based enrichment and creation of a guide for future analogue synthesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据